1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow Immune-Related Adverse Events: new trials by email Literature Review of Immune-Related Adverse Events trials Research Report on Immune-Related Adverse Events
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events Rituximab (RTX) - Immune-Related Adverse Events | Phase 1 | Recruiting | Inge Marie Svane | 25 | 2026-10-15 | 2026-10-20 |
Melanoma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
Rituximab (1)
Inge Marie Svane (1)
Denmark (1)